HIGH POINT, N.C. --(BUSINESS WIRE)--Nov. 16, 2016-- vTv Therapeutics Inc. (vTv, Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered small molecule drug candidates to fill significant unmet medical needs, today announced that
HIGH POINT, N.C. --(BUSINESS WIRE)--Nov. 10, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that it will be participating in
HIGH POINT, N.C. --(BUSINESS WIRE)--Nov. 2, 2016-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today provided a corporate update and
HIGH POINT, N.C. --(BUSINESS WIRE)--Oct. 24, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that the company’s Chief
HIGH POINT, N.C. --(BUSINESS WIRE)--Oct. 3, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company committed to the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, announced today that company Chief Medical
HIGH POINT, N.C. --(BUSINESS WIRE)--Sep. 8, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that Company management will
Phase 2b Trial Showed Positive Results In Slowing Cognitive Decline HIGH POINT, N.C. --(BUSINESS WIRE)--Sep. 7, 2016-- vTv Therapeutics Inc. (NASDAQ:VTVT) today announced the completion of enrollment for Part A of STEADFAST (Single Trial Evaluating Alzheimer’s Disease Following Addition to
HIGH POINT, N.C. --(BUSINESS WIRE)--Sep. 2, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that company Chief Medical Officer
TTP273 is an oral, small molecule GLP-1R agonist with best-in-class potential Company Releases Q2 Earnings Results and Details Upcoming Program Milestones HIGH POINT, N.C. --(BUSINESS WIRE)--Aug. 16, 2016-- vTv Therapeutics Inc. (vTv) (Nasdaq:VTVT), a clinical-stage biopharmaceutical company
Novel glucokinase activator shows sustained meaningful reduction in HbA1c with well-tolerated treatment regimen HIGH POINT, N.C. --(BUSINESS WIRE)--Aug. 10, 2016-- Please replace the release with the following corrected version due to multiple revisions.